<DOC>
	<DOCNO>NCT02626780</DOCNO>
	<brief_summary>The general objective study conduct safety feasibility study single injection autologous adipose-derived SVF treatment alopecia .</brief_summary>
	<brief_title>Adipose-derived SVF Treatment Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>1 . Males females 18 60 year age old diagnose androgenetic alopecia . 2 . Subjects good health ( ASA Class III ) BMI &lt; 35 . Must least 2cm x 2cm spot scalp show evidence alopecia without scar traumatic injury 3 . Able willing make require study visit . 4 . Able willing give consent follow study instruction . 5 . Must speak , read understand English 1 . History bleed disorder , anticoagulation therapy stop 14 day prior injection 2 . Allergic lidocaine , epinephrine , valium sodium phosphate 3 . Individuals propensity keloids 4 . Individuals diminish decisionmaking capacity include research study 5 . Current use antiinflammatory anticoagulation medication affect bleed bleeding disorder . These include : Plavix , Warfarin ( Coumadin , Jantoven , Marfarin ) . In addition , follow medicine use two ( 2 ) week prior surgery patient ineligible . 6 . Use concomitant treatment , include topical medication , oral medication , mesotherapy , nonablative fractional laser treatment , lowlevel laser therapy , interfollicular PRP injection hair transplantation within precede 6 month . 7 . All smoker tobacco user .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>